SGRY - Surgery Partners, Inc.
NASDAQ
->
Healthcare
->
Medical Care Facilities
Brentwood,
United States
Type: Equity
SGRY price evolution
SGRY
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $213.5 | $185.2 | $195.9 | |
| Short term investments | ||||
| Net receivables | $542.9 | $523.4 | $494.3 | $496.4 |
| Inventory | $82 | $80.9 | $77 | $75.2 |
| Total current assets | $1035.8 | $1012.5 | $895.9 | $895 |
| Long term investments | $227.1 | $188.7 | $184.1 | |
| Property, plant & equipment | $1302 | $1272.7 | $1240.5 | $1224 |
| Goodwill & intangible assets | $4858.5 | $4451.1 | $4380.8 | |
| Total noncurrent assets | $6476.1 | $6079.7 | $5981.7 | |
| Total investments | $227.1 | $188.7 | $184.1 | |
| Total assets | $7534.4 | $7488.6 | $6975.6 | $6876.7 |
| Current liabilities | ||||
| Accounts payable | $170.8 | $174 | $174.1 | $171.8 |
| Deferred revenue | ||||
| Short long term debt | $92.4 | $77.2 | $73.3 | |
| Total current liabilities | $575.2 | $551.8 | $523.4 | $523 |
| Long term debt | $3094.2 | $3297.3 | $3044.3 | $2950.7 |
| Total noncurrent liabilities | $3760.5 | $3414.3 | $3319.2 | |
| Total debt | $3389.7 | $3121.5 | $3024 | |
| Total liabilities | $5637.9 | $4312.3 | $3937.7 | $3842.2 |
| Shareholders' equity | ||||
| Retained earnings | -$628.8 | -$597.1 | -$581.6 | -$569.2 |
| Other shareholder equity | $10.5 | $37.1 | $52 | $57.5 |
| Total shareholder equity | $1952.4 | $1967.3 | $1987.2 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $195.9 | $282.9 | $389.9 | $317.9 |
| Short term investments | ||||
| Net receivables | $496.4 | $456.3 | $430.2 | $382.2 |
| Inventory | $75.2 | $71.4 | $61.1 | $56.4 |
| Total current assets | $895 | $921 | $946.1 | $801.5 |
| Long term investments | $184.1 | $190.3 | $88.7 | $90.3 |
| Property, plant & equipment | $1224 | $1155.7 | $953.8 | $854.7 |
| Goodwill & intangible assets | $4380.8 | $4179.4 | $3955.5 | $3514.9 |
| Total noncurrent assets | $5981.7 | $5761.1 | $5171.5 | $4611.7 |
| Total investments | $184.1 | $190.3 | $88.7 | $90.3 |
| Total assets | $6876.7 | $6682.1 | $6117.6 | $5413.2 |
| Current liabilities | ||||
| Accounts payable | $171.8 | $151.6 | $124.9 | $100.2 |
| Deferred revenue | $3.2 | $64.4 | $109.8 | |
| Short long term debt | $73.3 | $62.8 | $60.4 | $64.4 |
| Total current liabilities | $523 | $493.4 | $536.8 | $556.8 |
| Long term debt | $2950.7 | $2559 | $3194 | $3093.3 |
| Total noncurrent liabilities | $3319.2 | $3247.8 | $3611.2 | $3974.3 |
| Total debt | $3024 | $2893.2 | $3254.4 | $3157.7 |
| Total liabilities | $3842.2 | $4683.9 | $4148 | $4531.1 |
| Shareholders' equity | ||||
| Retained earnings | -$569.2 | -$557.3 | -$502.7 | -$431.8 |
| Other shareholder equity | $57.5 | $76.2 | -$31.5 | -$61 |
| Total shareholder equity | $1987.2 | $1998.2 | $1089 | $115.6 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $770.4 | $762.1 | $717.4 | $735.4 |
| Cost of revenue | $582.9 | $562.1 | $541.8 | |
| Gross Profit | $201.4 | $179.2 | $155.3 | $193.6 |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | $40.3 | $33.2 | $20.9 | |
| Total operating expenses | $101.1 | $93.7 | $82 | $81.5 |
| Operating income | $85.5 | $73.3 | $112.1 | |
| Income from continuing operations | ||||
| EBIT | $40.9 | $39.3 | $53.7 | |
| Income tax expense | $4.5 | $4.9 | $4.4 | $6 |
| Interest expense | -$44.8 | $51.5 | $47.3 | $48.7 |
| Net income | ||||
| Net income | -$31.7 | -$15.5 | -$12.4 | -$1 |
| Income (for common shares) | -$15.5 | -$12.4 | -$1 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $2743.3 | $2539.3 | $2225.1 | $1860.1 |
| Cost of revenue | $2095.8 | $1964.4 | $1733.7 | $1480.3 |
| Gross Profit | $647.5 | $574.9 | $491.4 | $379.8 |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | $120.9 | $102.2 | $104 | $97.1 |
| Total operating expenses | $318.2 | $227.3 | $191.4 | $207.6 |
| Operating income | $329.3 | $347.6 | $300 | $172.2 |
| Income from continuing operations | ||||
| EBIT | $180.8 | $203.6 | $160.6 | $65.6 |
| Income tax expense | -$0.3 | $23.3 | $10.5 | -$20.1 |
| Interest expense | $193 | $234.9 | $221 | $201.8 |
| Net income | ||||
| Net income | -$11.9 | -$54.6 | -$70.9 | -$116.1 |
| Income (for common shares) | -$11.9 | -$54.6 | -$81.2 | -$155.6 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$15.5 | -$12.4 | -$1 | |
| Operating activities | ||||
| Depreciation | $44.5 | $42.7 | $39.9 | |
| Business acquisitions & disposals | -$210 | -$54.6 | -$31.2 | |
| Stock-based compensation | $15.1 | $4.9 | $4.5 | |
| Total cash flows from operations | $82.8 | $40.7 | $62.6 | |
| Investing activities | ||||
| Capital expenditures | -$26.9 | -$19.5 | -$19.8 | |
| Investments | $4.3 | -$2 | $0.3 | |
| Total cash flows from investing | -$376.8 | -$244.1 | -$83.1 | -$58.1 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | $234.4 | $72.3 | -$15.6 | |
| Total cash flows from financing | $214 | $189.6 | $31.7 | -$44.6 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $25.9 | $28.3 | -$10.7 | -$40.1 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$11.9 | -$54.6 | -$70.9 | -$116.1 |
| Operating activities | ||||
| Depreciation | $153.3 | $149.6 | $137.9 | $134.2 |
| Business acquisitions & disposals | -$80 | -$146.4 | -$285.8 | -$104.6 |
| Stock-based compensation | $17.7 | $18.4 | $17.4 | $13.2 |
| Total cash flows from operations | $293.8 | $158.8 | $87.1 | $246.9 |
| Investing activities | ||||
| Capital expenditures | -$63 | -$67.7 | -$51.6 | $15.6 |
| Investments | -$48.9 | -$82.3 | $5.4 | |
| Total cash flows from investing | -$225.6 | -$307.9 | -$331.7 | -$88.4 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $857.7 | $554.2 | ||
| Net borrowings | -$4.8 | -$655.5 | -$55.5 | $204.6 |
| Total cash flows from financing | -$155.2 | $42.1 | $316.3 | $66.7 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$87 | -$107 | $71.7 | $225.2 |
News
Fundamentals
| Market cap | $2.90B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 127.13M |
| Revenue | $2.99B |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$60.60M |
| Revenue Q/Q | 14.29% |
| Revenue Y/Y | 9.96% |
| P/E ratio | -47.89 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 0.97 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$0.48 |
|---|---|
| ROA | -0.84% |
| ROE | N/A |
| Debt/Equity | 1.93 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 1.80 |
| Quick ratio | 1.66 |